Italia markets open in 8 hours 9 minutes

Genetic Technologies Limited (0A4N.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,4420-0,6380 (-30,67%)
Alla chiusura: 07:11PM BST
Schermo intero
Chiusura precedente2,0800
Aperto1,4420
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno1,4420 - 1,4420
Intervallo di 52 settimane1,4420 - 1,4420
Volume100
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)1,25
Rapporto PE (ttm)N/D
EPS (ttm)-0,6000
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Acquisition of global direct to consumer ecommerce business

    MELBOURNE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease advises that it has entered into an agreement to acquire the direct-to-consumer eCommerce business and distribution rights associated with AffinityDNA. Acquisition Highlights Strategic acquisition continues to strengthen the direct-to-consumer channel for GENE.Provides an additional platfor

  • GlobeNewswire

    Genetic Technologies drives leadership in precision medicine with Multi-Risk Test

    MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness and serious disease provides its year to date results for the nine months ended March 31, 2022. Key Highlights Year to date growth in revenue of 475%Cash receipts of A$2 million in quarter 3, an increase of 9% on the prior quarter, and mainly comprising EasyDNA product salesGeneType Multi-Risk Test re

  • GlobeNewswire

    US Patent Office Grants Patent for COVID-19 Risk Test

    MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the granting of US Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection. The granted US patent covers the proprietary technology incorporated into GENE’s geneType COVID-19 Risk Test, which provides a probability